AbstractObjectivesThis study aimed to investigate the levels of brain iron deposition in Parkinson’s disease (PD) patients using Quantitative Susceptibility Mapping (QSM) and to determine whether distinctions compared to the general population exist. Furthermore, we examined potential variations in iron deposition among different PD subtypes.
MethodsStructural brain imaging was conducted on 75 participants at Gangdong Kyung Hee University Hospital between August 2017 and May 2020. PD patients were categorized into Tremor Dominant (TD) and Postural Instability and Gait Difficulty (PIGD) subtypes. Voxel-based morphometry and QSM were employed to compare voxel-wise magnetic susceptibility across the entire brain between Normal Controls (NC) and PD groups. Subsequently, QSM values were compared between TD and PIGD groups.
ResultsQSM values were compared among 46 PD patients and 23 normal controls, as well as between TD (n=22) and PIGD (n=24) groups. Voxel-based QSM analysis revealed no significant differences between groups. Similarly, ROI-based QSM analysis showed no significant distinctions.
ConclusionsNo significant variations were observed between the PD patient group, NC group, or PD subtypes. This study systematically compared QSM values across a broad range of brain regions potentially linked to PD pathology. Additionally, the subdivision of the PD group into TD and PIGD subtypes for QSM-based iron deposition analysis represents a meaningful and innovative approach.
참고문헌1. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci, 20(4), 415-55.
https://doi.org/10.1016/0022-510X(73)90175-5
![]() ![]() 2. Fearnley, J. M., & Lees, A. J. (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain, 114(5), 2283-2301.
https://doi.org/10.1093/brain/114.5.2283
![]() ![]() 3. de Rijk, M. C., Rocca, W. A., Anderson, D. W., Melcon, M. O., Breteler, M. M., & Maraganore, D. M. (1997). A population perspective on diagnostic criteria for Parkinson’s disease. Neurology, 48(5), 1277-81.
https://doi.org/10.1212/WNL.48.5.1277
![]() ![]() 4. Deistung, A., Schweser, F., & Reichenbach, J. R. (2017). Overview of quantitative susceptibility mapping. NMR Biomed, 30(4), e3569.
https://doi.org/10.1002/nbm.3569
5. Haacke, E. M., Liu, S., Buch, S., Zheng, W., Wu, D., & Ye, Y. (2014). Quantitative susceptibility mapping: current status and future directions. Magn Reson Imaging, 33(1), 1-25.
https://doi.org/10.1016/j.mri.2014.09.004
![]() ![]() 6. Ward, R., Zucca, F., Duyn, J., Crichton, R., & Zecca, L. (2014). The role of iron in brain (160) ageing and neurodegenerative disorders. Lancet Neurol, 13(10), 1045-60.
https://doi.org/10.1016/S1474-4422(14)70117-6
![]() ![]() 7. Thenganatt, M. A., & Jankovic, J. (2014). Parkinson Disease Subtypes. JAMA Neurol, 71(4), 499-504.
https://doi.org/10.1001/jamaneurol.2013.6233
![]() ![]() 8. Sethi, K. (2008). Levodopa unresponsive symptoms in Parkinson disease. Mov Disord, 23(S3), 521-33.
https://doi.org/10.1002/mds.22049
9. Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., & Golbeet, L., et al (1990). Parkinson Study Group. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. Neurology, 40(10), 1529-34.
https://doi.org/10.1212/WNL.40.10.1529
![]() ![]() 10. Rosenberg-Katz, K., Herman, T., Jacob, Y., Giladi, N., Hendler, T., & Hausdorff, J. M. (2013). Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology, 80(16), 1476-84.
https://doi.org/10.1212/WNL.0b013e31828cfaa4
![]() ![]() ![]() 11. Calne, D. B., Snow, B. J., & Lee, C. (1992). Criteria for diagnosing Parkinson’s disease. Ann Neurol, 32(S1), 125-7.
https://doi.org/10.1002/ana.410320721
![]() ![]() 12. Bagher-Ebadian, H., Jiang, Q., & Ewing, J. R. (2008). A modified fourier-based phase unwrapping algorithm with an application to MRI venography. J Magn Reson Imaging, 27(3), 649-52.
https://doi.org/10.1002/jmri.21230
![]() ![]() ![]() 13. Haacke, E. M., Cheng, N. Y., House, M. J., Liu, Q., Neelavalli, J., & Ogg, R. J., et al (2005). Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging, 23(1), 1-25.
https://doi.org/10.1016/j.mri.2004.10.001
![]() ![]() 14. Braak, H., Tredici, K. D., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging, 24(2), 197-211.
https://doi.org/10.1016/S0197-4580(02)00065-9
![]() ![]() 15. Sian-Hulsmann, J., Mandel, S., Youdim, M. B., & Riederer, P. (2011). The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem, 118(6), 939-57.
https://doi.org/10.1111/j.1471-4159.2010.07132.x
![]() ![]() 16. Uchida, Y., Kan, H., Sakurai, K., Arai, N., Kato, D., & Kawashima, S., et al (2019). Voxel-based quantitative susceptibility mapping in Parkinson’s disease with mild cognitive impairment. Movement Disorders, 34(8), 1164-73.
https://doi.org/10.1002/mds.27717
![]() 17. Deh, K., Nguyen, T. D., Eskreis-Winkler, S., Prince, M. R., Spincemaille, P., & Gauthier, S., et al (2015). Reproducibility of quantitative susceptibility mapping in the brain at two field strengths from two vendors. J Magn Reson Imaging, 42(6), 1592-1600.
https://doi.org/10.1002/jmri.24943
![]() ![]() ![]() 18. Ravanfar, P., Loi, S. M., Syeda, W. T., Van Rheenen, T. E., Bush, A. I., & Desmond, P., et al (2021). Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases. Front. Neurosci, 15, 618435.
https://doi.org/10.3389/fnins.2021.618435
![]() ![]() ![]() 19. Mazzucchi, S., Frosini, D., Costagli, M., Del Prete, E., Donatelli, G., & Cecchi, P., et al (2019). Quantitative susceptibility mapping in atypical Parkinsonisms. Neuroimage Clin, 24, 101999.
https://doi.org/10.1016/j.nicl.2019.101999
![]() ![]() ![]() 20. Guan, X., Xuan, M., Gu, Q., Xu, X., Huang, P., & Wang, N., et al (2017). Influence of regional iron on the motor impairments of Parkinson’s disease: a quantitative susceptibility mapping study. J Magn Reson Imaging, 45(5), 1335-42.
https://doi.org/10.1002/jmri.25434
![]() 21. Alves, G., Larsen, J. P., Emre, M., Wentzel-Larsen, T., & Aarsland, D. (2006). Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord, 21(8), 1123-30.
https://doi.org/10.1002/mds.20897
![]() ![]() 22. Nègre-Pagès, L., Grandjean, H., Lapeyre-Mestre, M., Montastruc, J. L., Fourrier, A., & Lépine, J. P., et al (2010). Anxious and depressive symptoms in Parkinson’s disease: the French cross-sectional DoPaMiP study. Mov Disord, 25(2), 157-66.
https://doi.org/10.1002/mds.22760
![]() 23. Burn, D. J., Landau, S., Hindle, J. V., Samuel, M., Wilson, K. C., & Hurt, C. S., et al (2012). Parkinson’s disease motor subtypes and mood. Mov Disord, 27(3), 379-86.
https://doi.org/10.1002/mds.24041
![]() 24. Iijima, M., Kobayakawa, T., Saito, S., Osawa, M., Tsutsumi, Y., & Hashimotoet, S., et al (2011). Differences in odor identification among clinical subtypes of Parkinson’s disease. Eur J Neurol, 18(3), 425-29.
https://doi.org/10.1111/j.1468-1331.2010.03167.x
![]() ![]() 25. Moreau, C., Delval, A., Defebvre, L., Dujardin, K., Duhamel, A., & Petytet, G., et al (2012). Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol, 11(7), 589-96.
https://doi.org/10.1016/S1474-4422(12)70106-0
![]() ![]() 26. Shahmaei, V., Faeghi, F., Mohammadbeigi, A., Hashemi, H., & Ashrafi, F. (2019). Evaluation of iron deposition in brain basal ganglia of patients with Parkinson’s disease using quantitative susceptibility mapping. European Journal of Radiology Open, 6, 169-74.
https://doi.org/10.1016/j.ejro.2019.04.005
![]() ![]() ![]() |
|